ICP
CRL icon

Interchange Capital Partners’s Charles River Laboratories CRL Stock Holding History

Interchange Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,368
Closed -$273K – 341
2025
Q4 		$273K Buy
+1,368
New +$248K 0.05% 326
2021
Q1 		– Sell
-79
Closed -$19K – 409
2020
Q4 		$19K Buy
+79
New +$18.8K 0.01% 642

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Interchange Capital Partners's CRL Position: Q1 2026 in Review

Interchange Capital Partners sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 1,368 shares — an estimated $273K sold.

Interchange Capital Partners first reported a position in CRL in Q4 2020 and held it in 2 quarters. The position peaked at $273K in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Interchange Capital Partners reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Interchange Capital Partners sold 1,368 Charles River Laboratories shares in Q1 2026, an estimated $273K.
  • Interchange Capital Partners first reported a position in Charles River Laboratories in Q4 2020 and held it in 2 quarters.
  • Interchange Capital Partners's Charles River Laboratories position peaked at $273K in Q4 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.